Antivirals For COVID

Richard Marsden, CEO of Synairgen plc discusses full results from its SGO16 Phase II trial of its inhaled interferon beta formulation (SNG001) for the treatment of severe viral lung infections in COVID-19 patients.  The combined analysis of the home and hospital cohorts shows that breathless patients are more than 3 times as likely to recover on SNG001 than placebo. Unique to SNG001 is that it is inhaled therefore targeting response at the site of infection. 

Richard Marsden joined Synairgen in a consulting role as General Manager in November 2003, was appointed to the Board as Managing Director in June 2004 and appointed Chief Executive Officer in September 2009. Between 1998 and 2003 he worked as Projects Manager and Cystic Fibrosis Business Development Manager at Profile Therapeutics plc, where he managed the Cystic Fibrosis business and played a major role in the development of its proprietary pharmaceutical unit, Profile Pharma Limited. Prior to this, he worked for Zimmer Limited, Genentech (UK) Limited and Roche Products Limited.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.